Cough and Cold · Antitussive
The FDA's approval of Aurobindo's Dextromethorphan Polistirex introduces a new competitor in the cough and cold market, which could disrupt existing market dynamics. Portfolio teams need to evaluate the implications for their current products and strategize accordingly.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/27/2026, 6:33:48 AM
Assessment confidence: 76% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval of Aurobindo's Dextromethorphan Polistirex introduces a new competitor in the cough and cold market, which could disrupt existing market dynamics. Portfolio teams need to evaluate the implications for their current products and strategize accordingly. Regulatory context from FDA (FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)) supports the near-term read. Assessment grounded in 11 ranked evidence items (8 high-relevance).
Portfolio teams should assess the impact of this approval on existing cough and cold products and consider strategic positioning. The strongest clinical anchor is A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants W (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In rare disease, 8 regulatory and 1 competitive items passed relevance filtering for Aurobindo Pharma.
The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). This approval allows Aurobindo to enter the market for cough and cold treatments, potentially increasing competition against established players.
Regulatory risk is concentrated around FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG) (FDA). Sub-indication match (rare disease); Entity match (aurobindo pharma). This approval signifies a shift in the regulatory landscape for cough and cold treatments, which may prompt other companies to reassess their product development and approval strategies.
FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Entity match (aurobindo pharma)
FDA document
View sourceFDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceRare Disease Drug Approvals
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (approval)
FDA document
View sourceFDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceAdvancing Novel Surrogate Endpoints For Rare Disease Drug Development Workshop - 05/18/2026
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View sourceA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants W
ClinicalTrials.govmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View sourceA Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePartial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceA Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceU.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View sourceFDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride)
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
A comprehensive review on Jiao-tai-wan: Traditional application, pharmacokinetics, and therapeutic mechanisms in multiple disorders.
PubMedmedium relevance
Mechanism alignment (IO )
FDA document
View sourceSanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceAn integrated approach combining transcriptomics, network pharmacology, and experimental validation are used to investigate the mechanism of Lonicerae Japonicae Flos and Forsythiae Fructus extracts ag
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceDevelopment and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of Aurobindo's Dextromethorphan Polistirex introduces a new competitor in the cough and cold market, which could disrupt existing market dynamics. Portfolio teams need to evaluate the implications for their current products and strategize accordingly.
Aurobindo's entry may lead to increased competition, potentially affecting market share and pricing strategies for established players in the cough and cold segment.
This approval signifies a shift in the regulatory landscape for cough and cold treatments, which may prompt other companies to reassess their product development and approval strategies.
Monitor market entry timelines and sales performance of Dextromethorphan Polistirex post-approval.
Track for follow-up milestones; no immediate action required.